[1] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, Chen HD, Chen JY, Luo, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao G. & Shi ZA (2020). pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273.
[2] Morse JS, Lalonde TS, Xu & Ray, Liu W (2020) Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV. ChemBioChem. 21:730 – 738
[3] Li F, Li W, Farzan M, Harrison SC (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 309:1864–1868.
[4] Dong N, Yang X, Ye L, Chen K, Chan E, Yang M, Chen S (2020) Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China, bioRxiv, https://www.biorxiv.org/content/10.1101/2020.01.20.913368v2 (accessed Jan. 25, 2020).
[5] Baranov P, Henderson VCM, Anderson CB, Gesteland RF, Atkins JF, Howard MT (2005) Programmed ribosomal frameshifting in decoding the SARS-CoV genome. Virology. 332:498–510.
[6] Ziebuhr J, Snijder EJ, Gorbalenya AE, (2000) Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 81:853 –879.
[7] Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J (2003) Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design, Nucleic Acids Res. 31:7117–7130.
[8] Li CC, Wang XJ, Wang HCR (2019) Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today 24:726 –736.
[9] Liu X, Zhang B, Jin Z, Yang H, Rao Z The crystal structure of COVID-19 main protease in complex with an inhibitor N3, [10.2210/pdb6LU7/pdb]
[10] Al-Osai AM, Al-WazzM J ah. (2017) The history and epidemiology of Middle East respiratory syndrome corona virus. Multidiscip Respir Med. 12:20. (doi: 10.1186/s40248-017-0101-8)
[11] Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, Kumar S, Bhattacharyya A, Kumar H, Bansal S, Medhi B (2020) Drug targets for corona virus: A systematic review, Indian Journal of Pharmacology. 52:56-65.
[12] Gralinski L, Menachery V (2020) Return of the Coronavirus: 2019-nCoV. Viruses. 24:135.
[13] Roosa S, Tikkanen MPH, Res M, Eric C, Schneider M.D.(2021) Social Spending to Improve Population Health — Does the United States Spend as Wisely as Other Countries? The New England journal of medicine. 382:885-887.
[14] Liang C, Tian L, Liu Y, Hui N, Qiao G, Li H (2020) A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. European journal of medicinal chemistry. 201:112527.
[15] Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV). Bioscience trends. 14:69–71.
[16] Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, et al. (2020) Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. The Journal of infection. 81:e21–e3.
[17] Spezzani V, Piunno A, Iselin H (2020) Benign COVID-19 in an immunocompromised cancer patient—the case of a married couple. Swiss medical weekly. 150:w20246.
[18] Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee D, Barnard et al. (2009)T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral research, 82:95–102.
[19] Ferron F, Subissi L, Silveira De Morais AT, Le, NTT,. Sevajol M, Gluais L, et al.(2018) Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proceedings of the National Academy of Sciences. 115:E162–e71.
[20] Krajczyk A, Kulinska K, Kulinski T, Hurst BL, Day CW, Smee DF et al.(2014) Antivirally active ribavirin analogues—4,5-disubstituted 1,2,3-triazole nucleosides: biological evaluation against certain respiratory viruses and computational modelling. Antivir Chem Chemother. 23:161–71.
[21] Tilmanis DC, van Baalen, Oh DY, Rossignol JF, Hurt AC, (2017) The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide. Antiviral Res.147:142–148.
[22] Pepperrell T, Pilkington V, Owen A, Wang J, Hill AM, (2020). Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19. Journal of virus eradication.6:52–60.
[23] Fantini J, Di Scala C, Chahinian H, Yahi N. (2020). Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 55:105960.
[24] Jr. Hall DC, Ji HF (2020). A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis.35:101646.
[25] Allergy Symptoms vs. Coronavirus (COVID-19), WebMD, [https://www.webmd.com/lung/
covid-allergies]
[26] Shoemaker, QB, Thiessen A, Yu PA Pub. Chem. (2019) .Update: Improved Access to Chemical Data. Nucleic Acids Res. 47:D1102−D1109.
[27] Berman H, Battistuz MT, Bhat TN, Bluhm WF, Bourne PE, Burkhardt K, Feng Z, Gilliland GL, Iype L, Jain S et al(2002). The Protein Data Bank. Acta Crystallogr. Sect. D: Biol. Crystallogr. 58:899−907.
[28] Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, Heer FTT, De Beer AP, Rempfer C, Bordoli L, et al. (2018). SWISS-MODEL: Homology Modelling of Protein Structures and Complexes. Nucleic Acids Res;46:W296− W303.
[29] Zhang L, Zhou R (2020). Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase. J. Phys. Chem. B. 124:6955−6962.
[30] Dallakyan S, Olson AJ (2016).Small-Molecule Library Screening by Docking with PyRx. Methods. Mol. Biol.;1263:243−50.
[31] Wakchaure PD, Ghosh S, Ganguly B (2020) Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study. The Journal of Physical Chemistry B. ;124:10641-10652.
[32] Dassault Systèmes, BIOVIA (2016). Discovery Studio Modeling Environment, Release 2017, San Diego: Dassault Systèmes,.
[33] Wakchaure PD, Velayutham R, Roy KK (2019). Structure investigation, enrichment analysis and structure-based repurposing of FDA-approved drugs as inhibitors of BET-BRD4. Journal of Biomolecular Structure and Dynamics.; 37: 3048-3057.
[34] Si MK, Sen A. & Ganguly B. (2017) Exploiting hydrogen bonding interactions to probe smaller linear and cyclic diamines binding to G-quadruplexes: a DFT and molecular dynamics study. J. Phys. Chem. Chem. Phys. 19:11474.
[35] Shi D, Heel house DS & Hurley LH (2001) Quadruplex-Interactive Agents as Telomerase Inhibitors: Synthesis of Porphyrins and Structure−Activity Relationship for the Inhibition of Telomerase. J. Med. Chem. 44:4509–4523.
[36] Bussi G, Donadio D & Parrinello M (2007) Canonical sampling through velocity rescalingJ. Chem. Phys., 126, 014101.
[37] Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A & Haak JR (1984) Molecular dynamics with coupling to an external bath J. Chem. Phys., 81, 3684–3690.